Lupin Ltd, India's fourth-largest drugmaker by sales, expects to launch three to four new generic drugs in its key US market by March end, its Group President Nilesh Gupta said on Thursday.
The Mumbai-based drugmaker has so far launched six products in this fiscal in the United States, which generates about 42% of its total formulation sales.
The drugmaker earlier reported a forecast-beating 42.6% rise in quarterly net profit to Rs 335 crore.
